Literature DB >> 17283127

Pten loss in the mouse thyroid causes goiter and follicular adenomas: insights into thyroid function and Cowden disease pathogenesis.

Nicole Yeager1, Andres Klein-Szanto, Shioko Kimura, Antonio Di Cristofano.   

Abstract

Inactivation and silencing of the tumor suppressor PTEN are found in many different epithelial tumors, including thyroid neoplasia. Cowden Disease patients, who harbor germ-line PTEN mutations, often display thyroid abnormalities, including multinodular goiter and follicular adenomas, and are at increased risk of thyroid cancer. To gain insights into the role PTEN plays in thyroid function and disease, we have generated a mouse strain, in which Cre-mediated recombination is used to specifically delete Pten in the thyrocytes. We found that Pten mutant mice develop diffuse goiter characterized by extremely enlarged follicles, in the presence of normal thyroid-stimulating hormone and T4 hormone levels. Loss of Pten resulted in a significant increase in the thyrocyte proliferative index, which was more prominent in the female mice, and in increased cell density in the female thyroid glands. Surprisingly, goitrogen treatment did not cause a substantial increase of the mutant thyroid size and increased only to some extent the proliferation index of the female thyrocytes, suggesting that a relevant part of the thyroid-stimulating hormone-induced proliferation signals are funneled through the phosphatidylinositol-3-kinase (PI3K)/Akt cascade. Although complete loss of Pten was not sufficient to cause invasive tumors, over two thirds of the mutant females developed follicular adenomas by 10 months of age, showing that loss of Pten renders the thyroid highly susceptible to neoplastic transformation through mechanisms that include increased thyrocyte proliferation. Our findings show that constitutive activation of the PI3K/Akt cascade is sufficient to stimulate continuous autonomous growth and provide novel clues to the pathogenesis of Cowden Disease and sporadic nontoxic goiter.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17283127     DOI: 10.1158/0008-5472.CAN-06-3524

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  54 in total

1.  Embryonic epithelial Pten deletion through Nkx2.1-cre leads to thyroid tumorigenesis in a strain-dependent manner.

Authors:  Saverio Bellusci; Parviz Minoo; Caterina Tiozzo; Soula Danopoulos; Maria Lavarreda-Pearce; Sheryl Baptista; Radka Varimezova; Denise Al Alam; David Warburton; Rehan Virender; Stijn De Langhe; Antonio Di Cristofano
Journal:  Endocr Relat Cancer       Date:  2012-04-10       Impact factor: 5.678

2.  Pioglitazone induces a proadipogenic antitumor response in mice with PAX8-PPARgamma fusion protein thyroid carcinoma.

Authors:  Melissa E Dobson; Ericka Diallo-Krou; Vladimir Grachtchouk; Jingcheng Yu; Lesley A Colby; John E Wilkinson; Thomas J Giordano; Ronald J Koenig
Journal:  Endocrinology       Date:  2011-09-27       Impact factor: 4.736

3.  MCM5 as a target of BET inhibitors in thyroid cancer cells.

Authors:  Catia Mio; Elisa Lavarone; Ketty Conzatti; Federica Baldan; Barbara Toffoletto; Cinzia Puppin; Sebastiano Filetti; Cosimo Durante; Diego Russo; Arturo Orlacchio; Antonio Di Cristofano; Carla Di Loreto; Giuseppe Damante
Journal:  Endocr Relat Cancer       Date:  2016-02-24       Impact factor: 5.678

4.  Inhibition of mTORC1 signaling reduces tumor growth but does not prevent cancer progression in a mouse model of thyroid cancer.

Authors:  Celine J Guigon; Laura Fozzatti; Changxue Lu; Mark C Willingham; Sheue-Yann Cheng
Journal:  Carcinogenesis       Date:  2010-03-18       Impact factor: 4.944

5.  Switch in signaling control of mTORC1 activity after oncoprotein expression in thyroid cancer cell lines.

Authors:  Roberta Malaguarnera; Kuen-Yuan Chen; Tae-Yong Kim; Jose M Dominguez; Francesca Voza; Bin Ouyang; Sushil K Vundavalli; Jeffrey A Knauf; James A Fagin
Journal:  J Clin Endocrinol Metab       Date:  2014-07-16       Impact factor: 5.958

Review 6.  Coding Molecular Determinants of Thyroid Cancer Development and Progression.

Authors:  Veronica Valvo; Carmelo Nucera
Journal:  Endocrinol Metab Clin North Am       Date:  2018-12-23       Impact factor: 4.741

7.  PTEN deficiency accelerates tumour progression in a mouse model of thyroid cancer.

Authors:  C J Guigon; L Zhao; M C Willingham; S-Y Cheng
Journal:  Oncogene       Date:  2008-11-10       Impact factor: 9.867

8.  Utility of PTEN protein dosage in predicting for underlying germline PTEN mutations among patients presenting with thyroid cancer and Cowden-like phenotypes.

Authors:  Joanne Ngeow; Xin He; Jessica L Mester; Junying Lei; Todd Romigh; Mohammed S Orloff; Mira Milas; Charis Eng
Journal:  J Clin Endocrinol Metab       Date:  2012-10-12       Impact factor: 5.958

9.  Cross-talk between PI3K and estrogen in the mouse thyroid predisposes to the development of follicular carcinomas with a higher incidence in females.

Authors:  V G Antico-Arciuch; M Dima; X-H Liao; S Refetoff; A Di Cristofano
Journal:  Oncogene       Date:  2010-08-02       Impact factor: 9.867

10.  Oncogenic Kras requires simultaneous PI3K signaling to induce ERK activation and transform thyroid epithelial cells in vivo.

Authors:  Kelly A Miller; Nicole Yeager; Kristen Baker; Xiao-Hui Liao; Samuel Refetoff; Antonio Di Cristofano
Journal:  Cancer Res       Date:  2009-04-07       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.